Akcea Therapeutics clinical trials
A subsidiary of Ionis Pharmaceuticals, Inc.
The registry lists 15 studies whose lead sponsor is Akcea Therapeutics. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 29, 2026.
Registry sponsor names on this page
- Akcea Therapeutics15 studies
Something wrong with this grouping? Tell us on the Ionis Pharmaceuticals, Inc. page.
Studies
Recruiting first, then most recently updated. Showing 15 of 15. All Ionis Pharmaceuticals, Inc. studies →
- TEGSEDI Pregnancy Surveillance ProgramNot yet recruitingNCT04270058
Sponsor listed in the registry: Akcea Therapeutics
- A Non-interventional Cohort Safety Study of Patients With hATTR-PNActive, not recruitingNCT04850105
Sponsor listed in the registry: Akcea Therapeutics
- A Study to Characterize Adverse Events Occurring Within One Day of TEGSEDI Administration to Adult Participants With hATTR-PNTerminatedNCT04306510Phase 4
Sponsor listed in the registry: Akcea Therapeutics
- Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)CompletedNCT03385239Phase 2
Sponsor listed in the registry: Akcea Therapeutics
- The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial LipodystrophyTerminatedNCT02527343Phase 2/3
Sponsor listed in the registry: Akcea Therapeutics
- Volanesorsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)No longer availableNCT03544060
Sponsor listed in the registry: Akcea Therapeutics
- The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia SyndromeCompletedNCT02658175Phase 3
Sponsor listed in the registry: Akcea Therapeutics
- Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)CompletedNCT03514420Phase 2
Sponsor listed in the registry: Akcea Therapeutics
- Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver DiseaseCompletedNCT03371355Phase 2
Sponsor listed in the registry: Akcea Therapeutics
- Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)CompletedNCT03360747Phase 2
Sponsor listed in the registry: Akcea Therapeutics
- Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular DiseaseCompletedNCT03070782Phase 2
Sponsor listed in the registry: Akcea Therapeutics
- Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy PatientsCompletedNCT03506854Phase 1
Sponsor listed in the registry: Akcea Therapeutics
- Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)WithdrawnNCT03455777Phase 2
Sponsor listed in the registry: Akcea Therapeutics
- Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on WarfarinCompletedNCT03426033Phase 1
Sponsor listed in the registry: Akcea Therapeutics
- Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on ClopidogrelCompletedNCT03392051Phase 1
Sponsor listed in the registry: Akcea Therapeutics